CytomX Therapeutics, Inc. (CTMX) vs MapLight Therapeutics, Inc. (MPLT)

CytomX Therapeutics, Inc. and MapLight Therapeutics, Inc. are both Biotechnology companies. CytomX Therapeutics, Inc. and MapLight Therapeutics, Inc. are of similar size ($599.2M and $587.7M). MapLight Therapeutics, Inc. has the higher net margin (0.00% vs −451.6%) and the lower return on invested capital (−348.4% vs 0.00%). Across the 12 metrics below, MapLight Therapeutics, Inc. leads on 7 and CytomX Therapeutics, Inc. on 5.

Valuation

Metric CTMX MPLT Biotechnology median
P/E n/m n/m 7.88
P/S 32.30 n/m 11.47
P/B 1.96 1.36 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 14.45 n/m 10.73
Earnings yield (18.52%) (404.49%) (28.84%)
Free cash flow yield (13.98%) (36.85%) (23.03%)

Profitability

Metric CTMX MPLT Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (476.19%) 0.00% 0.00%
Net margin (451.62%) 0.00% 0.00%
Free cash flow margin (450.27%) 0.00% 0.00%
Return on equity (39.18%) (297.18%) (57.72%)
Return on assets (29.72%) (124.79%) (49.22%)
Return on invested capital 0.00% (348.44%) 0.00%

Growth

Metric CTMX MPLT Biotechnology median
Revenue growth (TTM) (87.03%) — 5.64%
EPS growth (last fiscal year) (139.47%) 82.39% —
Revenue growth, 5-year CAGR (5.36%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CTMX MPLT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.36 16.52 4.73
Net debt to EBITDA 5.91 1.79 0.96

Dividend

Metric CTMX MPLT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric CTMX MPLT Biotechnology median
Market cap 599.22m 587.68m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack